{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:20:14Z","timestamp":1792819214726,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12931-018-0859-z","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T13:52:31Z","timestamp":1534427551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review"],"prefix":"10.1186","volume":"19","author":[{"given":"Andrea","family":"Matucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"859_CR1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2017. http:\/\/ginasthma.org\/2017-gina-report-global-strategy-for-asthma-management-and-prevention ."},{"issue":"2","key":"859_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"key":"859_CR3","unstructured":"American Academy of Allergy, Asthma & Immunology. The prevalence of severe refractory asthma. 2014. http:\/\/www.aaaai.org\/global\/latest-research-summaries\/New-Research-from-JACI-In-Practice\/refractory-asthma ."},{"key":"859_CR4","volume-title":"Xolair\u00ae (omalizumab) for injection, for subcutaneous use","author":"US Food and Drug Administration","year":"2016","unstructured":"US Food and Drug Administration. Xolair\u00ae (omalizumab) for injection, for subcutaneous use. 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103976s5225lbl.pdf ."},{"key":"859_CR5","unstructured":"European Medicines Agency. Xolair 75 mg powder and solvent for solution for injection. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000606\/WC500057298.pdf ."},{"key":"859_CR6","volume-title":"Cinqair\u00ae (reslizumab) injection, for intravenous use","author":"US Food and Drug Administration","year":"2016","unstructured":"US Food and Drug Administration. Cinqair\u00ae (reslizumab) injection, for intravenous use. 2016. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf ."},{"key":"859_CR7","volume-title":"Nucala\u00ae (mepolizumab) for injection, for subcutaneous use","author":"US Food and Drug Administration","year":"2015","unstructured":"US Food and Drug Administration. Nucala\u00ae (mepolizumab) for injection, for subcutaneous use. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125526s002lbl.pdf ."},{"key":"859_CR8","volume-title":"Fasenra (benralizumab) injection, for subcutaneous use","author":"US Food and Drug Administration","year":"2017","unstructured":"US Food and Drug Administration. Fasenra (benralizumab) injection, for subcutaneous use. 2017. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761070Orig1s000Lbl.pdf ."},{"key":"859_CR9","volume-title":"Cinqaero 10 mg\/mL concentrate for solution for infusion","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Cinqaero 10 mg\/mL concentrate for solution for infusion. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003912\/WC500212250.pdf ."},{"key":"859_CR10","volume-title":"Nucala 100 mg powder for solution for injection","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Nucala 100 mg powder for solution for injection. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003860\/WC500198037.pdf ."},{"key":"859_CR11","volume-title":"Fasenra (benralizumab) summary of opinion (initial authorisation)","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Fasenra (benralizumab) summary of opinion (initial authorisation). 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/004433\/WC500238040.pdf ."},{"issue":"9","key":"859_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"859_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","volume":"9","author":"TT Hansel","year":"2010","unstructured":"Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9(4):325\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"859_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"859_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/clpt.2011.328","volume":"91","author":"I Ordas","year":"2012","unstructured":"Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635\u201346.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"859_CR16","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.5414\/CP202446","volume":"53","author":"IJ Pouliquen","year":"2015","unstructured":"Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015\u201327.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"17","key":"859_CR17","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1200\/JCO.2013.52.2631","volume":"32","author":"A Salar","year":"2014","unstructured":"Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32(17):1782\u201391.","journal-title":"J Clin Oncol"},{"issue":"6","key":"859_CR18","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","volume":"4","author":"A Davies","year":"2017","unstructured":"Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272\u201382.","journal-title":"Lancet Haematol"},{"issue":"9","key":"859_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S1470-2045(12)70329-7","volume":"13","author":"G Ismael","year":"2012","unstructured":"Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, et al. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869\u201378.","journal-title":"Lancet Oncol"},{"key":"859_CR20","volume-title":"Cinqaero (reslizumab) Public Assessment Report","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. Cinqaero (reslizumab) Public Assessment Report. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003912\/WC500212250.pdf ."},{"key":"859_CR21","unstructured":"Jaworowicz D, Fiedler-Kelly J, Rabinovich-Guilatt L, Bond M. The steady-state pharmacokinetic (PK) profile across a range of patient body weight categories supports weight-based dosing for intravenous (IV) reslizumab. Am J Respir Crit Care Med. 2016;193:A1389."},{"issue":"12","key":"859_CR22","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","volume":"21","author":"T Kouro","year":"2009","unstructured":"Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21(12):1303\u20139.","journal-title":"Int Immunol"},{"issue":"5","key":"859_CR23","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jaip.2017.02.002","volume":"5","author":"A Alhossan","year":"2017","unstructured":"Alhossan A, Lee CS, MacDonald K, Abraham I. \u201creal-life\u201d effectiveness studies of Omalizumab in adult patients with severe allergic asthma: meta-analysis. J Allergy Clin Immunol Pract. 2017;5(5):1362\u201370.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"859_CR24","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","volume":"103","author":"G Brusselle","year":"2009","unstructured":"Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al. \u201creal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med. 2009;103(11):1633\u201342.","journal-title":"Respir Med"},{"issue":"2","key":"859_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1067\/mai.2001.117880","volume":"108","author":"W Busse","year":"2001","unstructured":"Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184\u201390.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"859_CR26","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1183\/09031936.01.00092101","volume":"18","author":"M Sol\u00e8r","year":"2001","unstructured":"Sol\u00e8r M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18(2):254\u201361.","journal-title":"Eur Respir J"},{"issue":"6","key":"859_CR27","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/j.jaci.2016.04.009","volume":"137","author":"HC Oettgen","year":"2016","unstructured":"Oettgen HC. Fifty years later: emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases. J Allergy Clin Immunol. 2016;137(6):1631\u201345.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"859_CR28","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.4049\/jimmunol.154.12.6285","volume":"154","author":"D Maurer","year":"1995","unstructured":"Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, et al. The high affinity IgE receptor (fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol. 1995;154(12):6285\u201390.","journal-title":"J Immunol"},{"issue":"6","key":"859_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","volume":"170","author":"R Djukanovic","year":"2004","unstructured":"Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"859_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","volume":"34","author":"ST Holgate","year":"2004","unstructured":"Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34(4):632\u20138.","journal-title":"Clin Exp Allergy"},{"issue":"13","key":"859_CR31","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189\u201397.","journal-title":"N Engl J Med"},{"issue":"13","key":"859_CR32","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"5","key":"859_CR33","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","volume":"5","author":"GL Chupp","year":"2017","unstructured":"Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390\u2013400.","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"859_CR34","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115\u201327.","journal-title":"Lancet"},{"issue":"25","key":"859_CR35","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"issue":"12","key":"859_CR36","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1164\/rccm.200206-525OC","volume":"167","author":"JC Kips","year":"2003","unstructured":"Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"859_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"859_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.chest.2016.03.032","volume":"150","author":"L Bjermer","year":"2016","unstructured":"Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789\u201398.","journal-title":"Chest"},{"key":"859_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1183\/23120541.00004-2017","volume":"3","author":"G Brusselle","year":"2017","unstructured":"Brusselle G, Canvin J, Weiss S, Sun SX, Buhl R. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. ERJ Open Res. 2017;3:3.","journal-title":"ERJ Open Res"},{"issue":"8","key":"859_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/1753465817717134","volume":"11","author":"J M\u00e1spero","year":"2017","unstructured":"M\u00e1spero J. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. Ther Adv Respir Dis. 2017;11(8):311\u201325.","journal-title":"Ther Adv Respir Dis"},{"key":"859_CR41","first-page":"A7782","volume":"193","author":"ED Bateman","year":"2016","unstructured":"Bateman ED, Zangrilli J, Germinaro M, Weiss S, Castro M. Association between early improvements in lung function and asthma control with reslizumab and the annual rate of asthma exacerbations. Am J Respir Crit Care Med. 2016;193:A7782.","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 60","key":"859_CR42","first-page":"OA2998","volume":"48","author":"J Canvin","year":"2016","unstructured":"Canvin J, Noble R, Djukanovic R, Curran M, Weiss S, Torvinen S, et al. Late-breaking abstract: early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients. Eur Respir J. 2016;48(suppl 60):OA2998.","journal-title":"Eur Respir J"},{"issue":"2","key":"859_CR43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","volume":"14","author":"N Chirmule","year":"2012","unstructured":"Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy. AAPS J. 2012;14(2):296\u2013302.","journal-title":"AAPS J"},{"key":"859_CR44","doi-asserted-by":"crossref","unstructured":"Krishna M, Nadler SG. Immunogenicity to biotherapeutics \u2013 the role of anti-drug immune complexes. Front Immunol. 2016;7:1\u201313.","DOI":"10.3389\/fimmu.2016.00021"},{"key":"859_CR45","doi-asserted-by":"crossref","unstructured":"Smith A, Manoli H, Jaw S, Frutoz K, Epstein AL, Khawli LA, et al. Unraveling the effect of immunogenicity on the PK\/PD, efficacy, and safety of therapeutic proteins. J Immunol Res 2016;2016:2342187.","DOI":"10.1155\/2016\/2342187"},{"issue":"2","key":"859_CR46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1517\/14712598.2016.1118457","volume":"16","author":"CC Mok","year":"2016","unstructured":"Mok CC, Tsai WC, Chen DY, Wei JC. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(2):201\u201311.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"859_CR47","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.alit.2016.06.004","volume":"66","author":"H Odajima","year":"2017","unstructured":"Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106\u201315.","journal-title":"Allergol Int"},{"key":"859_CR48","doi-asserted-by":"crossref","unstructured":"Liao K, Meyer E, Lee TN, Loercher A, Sikkema D. Inhibition of interleukin-5 induced false positive anti-drug antibody responses against mepolizumab through the use of a competitive blocking antibody. J Immunol Methods. 2017:44115\u201323.","DOI":"10.1016\/j.jim.2016.11.010"},{"issue":"2","key":"859_CR49","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165\u201378.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"859_CR50","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552\u201363.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"859_CR51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s11095-013-0992-9","volume":"30","author":"G Kijanka","year":"2013","unstructured":"Kijanka G, Jiskoot W, Schellekens H, Brinks V. Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm Res. 2013;30(6):1553\u201360.","journal-title":"Pharm Res"},{"issue":"3","key":"859_CR52","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jconrel.2010.08.012","volume":"147","author":"D Mohanan","year":"2010","unstructured":"Mohanan D, Slutter B, Henriksen-Lacey M, Jiskoot W, Bouwstra JA, Perrie Y, et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J Control Release. 2010;147(3):342\u20139.","journal-title":"J Control Release"},{"issue":"6","key":"859_CR53","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, et al. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1078\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"859_CR54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/annonc\/mdu524","volume":"26","author":"C Jackisch","year":"2015","unstructured":"Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, et al. Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. Ann Oncol. 2015;26(2):320\u20135.","journal-title":"Ann Oncol"},{"issue":"2","key":"859_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdermsci.2014.08.012","volume":"77","author":"M Haniffa","year":"2015","unstructured":"Haniffa M, Gunawan M, Jardine L. Human skin dendritic cells in health and disease. J Dermatol Sci. 2015;77(2):85\u201392.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"859_CR56","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","volume":"15","author":"AM Fathallah","year":"2013","unstructured":"Fathallah AM, Bankert RB, Balu-Iyer SV. Immunogenicity of subcutaneously administered therapeutic proteins\u2014a mechanistic perspective. AAPS J. 2013;15(4):897\u2013900.","journal-title":"AAPS J"},{"issue":"2","key":"859_CR57","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1188\/10.CJON.E10-E21","volume":"14","author":"WH Vogel","year":"2010","unstructured":"Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10\u201321.","journal-title":"Clin J Oncol Nurs"},{"issue":"12","key":"859_CR58","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"46","author":"M Svenson","year":"2007","unstructured":"Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46(12):1828\u201334.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"859_CR59","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","volume":"65","author":"A Vultaggio","year":"2010","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Parronchi P, Rossi O, et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy. 2010;65(5):657\u201361.","journal-title":"Allergy"},{"issue":"3","key":"859_CR60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000336839","volume":"159","author":"A Vultaggio","year":"2012","unstructured":"Vultaggio A, Matucci A, Nencini F, Pratesi S, Petroni G, Cammelli D, et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol. 2012;159(3):321\u20136.","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"859_CR61","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/acr.22096","volume":"65","author":"MV Hernandez","year":"2013","unstructured":"Hernandez MV, Sanmarti R, Canete JD, Descalzo MA, Alsina M, Carmona L, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013;65(12):2024\u201331.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"859_CR62","volume-title":"Mepolizumab summary review of regulatory action","author":"European Medicines Agency","year":"2015","unstructured":"European Medicines Agency. Mepolizumab summary review of regulatory action. 2015. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125526Orig1s000SumR.pdf ."},{"issue":"4","key":"859_CR63","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","volume":"150","author":"J Corren","year":"2016","unstructured":"Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799\u2013810.","journal-title":"Chest"},{"key":"859_CR64","doi-asserted-by":"crossref","unstructured":"Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015:9923\u201342.","DOI":"10.2147\/PPA.S87271"},{"issue":"4","key":"859_CR65","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1055\/s-0034-1368173","volume":"74","author":"C Jackisch","year":"2014","unstructured":"Jackisch C, Muller V, Maintz C, Hell S, Ataseven B. Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Frauenheilkd. 2014;74(4):343\u20139.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"6","key":"859_CR66","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10067-017-3587-8","volume":"36","author":"M Desplats","year":"2017","unstructured":"Desplats M, Pascart T, Jelin G, Norberciak L, Philippe P, Houvenagel E, et al. Are abatacept and tocilizumab intravenous users willing to switch for the subcutaneous route of administration? A questionnaire-based study. Clin Rheumatol. 2017;36(6):1395\u2013400.","journal-title":"Clin Rheumatol"},{"issue":"9842","key":"859_CR67","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0859-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-018-0859-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0859-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T11:20:02Z","timestamp":1693826402000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-018-0859-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1186\/s12931-018-0859-z","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM and AV have received payment for lectures and consultant arrangements from Novartis, Glaxo-Smith-Kline, Teva, Astra-Zeneca. AM and AV have received research support from Novartis, Glaxo-Smith-Kline and Sanofi.RD receives research fundings from Pfizer, Boehringher, AstraZeneca, Novartis and Celgene and honoraria from Pfizer, Boehringher, AstraZeneca, Novartis, Janssen, Roche and Celgene. The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"154"}}